title: Alpha interferon as first line therapy for angioimmunoblastic lymphoadenopathy. Possible value of DR+ cells in monitoring therapeutical response.
authors.forename: G
authors.initials: G
authors.lastname: Milone
authors.forename: P
authors.initials: P
authors.lastname: Guglielmo
authors.forename: E
authors.initials: E
authors.lastname: Cacciola
authors.forename: D
authors.initials: D
authors.lastname: Calogero
authors.forename: R
authors.initials: R
authors.lastname: Giustolisi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000628:therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016130:Immunophenotyping; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016131:Lymphocyte Subsets / Q000276:immunology*; D008297:Male; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D015415:Biomarkers; D006684:HLA-DR Antigens; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins